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Abstract
Objectives To evaluate whether low PI-RADS v2 assessment categories are effective at excluding extraprostatic extension (EPE)
of prostate cancer (≥pT3a PCa).
Methods The local institutional ethics committee approved this retrospective analysis of 301 consecutive PCa patients. Patients
were classified as low- or intermediate/high-risk based on clinical parameters and underwent pre-surgical multiparametric
magnetic resonance imaging. A PI-RADS v2 assessment category and ESUR EPE score were assigned for each lesion by two
readers working in consensus. Histopathologic analysis of the whole-mount radical prostatectomy specimen was the reference
standard. Univariate and multivariate analyses were performed to evaluate the association of PI-RADS v2 assessment category
with final histology ≥pT3a PCa.
Results For a PI-RADS v2 assessment category threshold of 3, the overall performance for ruling out (sensitivity, negative
predictive value, negative likelihood ratio) ≥pT3a PCa was 99%/98%/0.04 and was similar in both the low-risk (96%/97%/0.12;
N = 137) and the intermediate/high-risk groups (100%/100%/0.0; N = 164). In univariate analysis, all clinical and tumor char-
acteristics except age were significantly associated with ≥pT3a PCa. In multivariate analysis, PI-RADS v2 assessment categories
≤ 3 had a protective effect relative to categories 4 and 5. The inclusion of ESUR EPE score improved the AUC of ≥pT3a PCa
prediction (from 0.73 to 0.86, p = 0.04 in the overall cohort). The impact of PI-RADS v2 assessment category is reflected in a
nomogram derived on the basis of our cohort.
Conclusions In our cohort, low PI-RADS v2 assessment categories of 3 or less confidently ruled out the presence of ≥pT3a PCa
irrespective of clinical risk group.
Key Points
• Our analysis of 301 mp-MRI and RARP specimens showed that the addition of PI-RADS v2 assessment categories to clinical
parameters improves the exclusion of ≥pT3a (extraprostatic) prostate cancer.
• PI-RADS v2 assessment categories of 1 to 3 are useful for excluding ≥pT3a prostate cancer with a NPVof 98%; such patients
can be considered as candidates for less invasive approaches.
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• The ability to exclude ≥pT3a prostate cancer may improve confidence in choosing nerve-sparing surgery or in avoiding pelvic
nodal dissections, and similarly for patients undergoing radiotherapy, in adopting short-course adjuvant hormonal therapy or
foregoing prophylactic nodal irradiation.
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Abbreviations
EAU European Association of Urology
EPE (≥pT3a) Extraprostatic extension
ESUR European Society of Urogenital Radiology
LR− Negative likelihood ratio
LR+ Positive likelihood ratio
PCa Prostate cancer
RARP Robotic-assisted radical prostatectomy
SE Sensitivity
SP Specificity
Introduction
The presence of extraprostatic extension (EPE) of disease in
prostate cancer (PCa) patients, corresponding to a pathologi-
cal stage of ≥pT3a at final histology,1 decreases overall and
cancer-specific survival following radical prostatectomy (RP)
[1]. This has led to interest in predicting the presence or ab-
sence of ≥pT3a PCa [2], as a non-invasive technique capable
of providing information regarding ≥pT3a PCa at the time of
diagnosis could influence decisions regarding treatment. In
particular, amongst men with low-risk disease, the absence
of ≥pT3a PCa can confirm the suitability of local control
(nerve-sparing surgery or radiotherapy) of PCa without a need
for adjunct treatment.
Multiparametric magnetic resonance imaging (mp-MRI) is
an established imaging technique for PCa detection [3, 4] and
has an established role for preoperative staging of PCa [5].
Mp-MRI is also of considerable value in the management of
low-risk PCa inmen under active surveillance (AS), because it
is effective in distinguishing significant from insignificant
cancer [6]. A standardized imaging technique and reporting
standard for mp-MRI has been created for PCa detection [3]
and has evolved into the Prostate Imaging Reporting and Data
System version 2 (PI-RADS v2) launched in 2014 [4, 7].
While not specifically designed for the staging of PCa, initial
reports by Park et al [8, 9] suggest PI-RADS v2 has potential
for predicting ≥pT3a PCa in the preoperative setting. An
extraprostatic extension score (ESUR EPE score) has also
been defined under ESUR guidelines for MRI [3] but is not
explicitly incorporated into the PI-RADS v2 criteria.
The purpose of our study was to evaluate whether low PI-
RADS v2 assessment categories are effective at excluding
EPE (≥pT3a) of PCa.
Materials and methods
This retrospective analysis was approved by our institution’s
ethics committee, who waived the requirement for a specific
informed consent for the study as all patients had given sepa-
rate written, informed consents for the performance of MRI,
for the surgical procedures, and for the use of their clinical
data for research purposes.
Patients
Inclusion criteria were as follows: (a) biopsy-confirmed PCa,
(b) mp-MRI, and (c) robotic-assisted radical prostatectomy
(RARP) performed at our institution based on clinical-
radiological indications or elective choice.
The exclusion criteria were as follows: contraindications
for MRI, and previous treatments or the assumption of 5a-
reductase inhibitors that could affect the performance of mp-
MRI or of final histology.
During the period of this retrospective study (July 2012 and
August 2013), 638 patients underwent mp-MRI at our institu-
tion, of whom 308 underwent RARP surgery on the basis of
clinical findings and personal health management decisions.
The time interval between biopsy and mp-MRI ranged from
20 to 50 days, while the time between mp-MRI and RARP
ranged from 1 to 3 months.
mp-MRI technique
PI-RADS v2–compliant prostate mp-MRI was performed on
a 1.5-T MR scanner (Avanto, Siemens Medical Solutions).
Anterior body (18 channel) and spinal (32 channel) phased-
array coils were used without endorectal coil, providing con-
sistently good image quality. The mp-MRI protocol
(Supplementary Table 1) involved sagittal, coronal, and axial
T2-weighted images; axial diffusion-weighted and pre-
contrast T1-weighted images; and a dynamic series of axial
T1-weighted images obtained before, during, and after injec-
tion of contrast agent (Magnevist, Bayer HealthCare).
1 Herein, we use the pathology stage ≥pT3a PCa to avoid possible confusion
with the European Society of UroRadiology extracapsular extension (ESUR
EPE) score [3].
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mp-MRI analysis
Two radiologists with respectively 3 and 2 years of experience
in mp-MRI of the prostate retrospectively read the images for
each patient separately, assigning a PI-RADS v2 assessment
category [4] for each lesion, and an ESUR EPE score for any
lesion in contact with the prostate capsule [3]. The radiologists
were blinded to the original radiological reports and patholog-
ical outcomes, but were aware that all patients had PCa, and
met for discussion of discordant readings, such that the final
PI-RADS v2 categories and ESUR EPE scores were assigned
by consensus.
Surgery
All surgical procedures were performed by surgeons with
more than 500 cases’ experience in RARP following an ap-
proach based on the technique described by Patel et al [10].
Intraoperative frozen section analysis was performed where
the index lesion was considered to have contact with the pros-
tatic capsule, and if the surgical margin was positive, a sec-
ondary resection was performed [11].
Pathology
The prostate total embedding of the whole-mount prostatecto-
my and any material from secondary resection were classified
according to the Gleason scoring system 2005 [12].
Pathologic stage was assigned using the 2009 TNM classifi-
cation [13], and extraprostatic extension assessed according to
BConsensus Prostate Working Group^ criteria [14].
Statistical analysis
Based on pre-imaging clinical characteristics, the patients
were divided into three risk groups according to EAU classi-
fication [15], but due to the small number of patients in the
high-risk group, the intermediate- and high-risk groups were
considered together as an Bintermediate/high-risk group.^
The radiological variables were considered at the patient
level, using the index lesion for each patient; when there were
several lesions in the gland, this corresponded to the lesion
with the highest PI-RADS score. If there were two lesions
with the same PI-RADS score, the lesion with the largest
diameter was considered the index lesion. Univariate analyses
were performed to evaluate the associations of clinical and
radiological variables with pathological stage ≥pT3a. For cat-
egorical variable, chi-square or Fisher’s exact tests were used,
as appropriate. For the continuous variable Bage,^ the non-
parametric two-sample Wilcoxon test was used, since the
Kolmogorov-Smirnov test suggested a non-normal distribu-
tion for this variable.
Sensitivity (SE), specificity (SP), positive predictive values
(PPV), negative predictive values (NPV), positive likelihood
ratio (LR+), and negative likelihood ratio (LR−) for predicting
pathological stage ≥pT3a were calculated for the following:
clinical risk group, ESUR EPE score, and PI-RADS v2 as-
sessment categories. The diagnostic performance was also
evaluated for ESUR EPE score and PI-RADS v2 assessment
categories stratified by clinical risk group. For these analyses,
ESUR EPE score and PI-RADS v2 assessment categories
were analyzed in two classes of cancer likelihood (≤ 3 vs. 4–
5), while for the univariate models, they were analyzed in
three classes (1–2 vs. 3 vs. 4–5).
Four unconditional logistic regression models for the asso-
ciation with ≥pT3a PCa were evaluated: model 1 included
only the clinical risk groups, model 2 added ESUR EPE score
to model 1, model 3 added the PI-RADS v2 assessment cate-
gory to model 1, and model 4 included clinical risk groups,
ESUR EPE score, and PI-RADS v2 assessment category.
Corresponding odds ratios (ORs) and 95% confidence inter-
vals (CI) were calculated for each model. The areas under the
receiver operating characteristic (ROC) curves (AUC) of the
four models were calculated and compared via the DeLong
test [16].
In addition, univariate and multivariate analyses were strat-
ified by clinical risk groups and reported as Supplementary
Material.
Finally, a nomogram for the prediction of ≥pT3a PCa find-
ings at pathology was created. Multivariable logistic regres-
sion was used to build the nomogram, considering the cate-
gorical variables: risk group, ESUR EPE score, and PI-RADS
v2 assessment category. Performance of the nomogram was
assessed in terms of discrimination (Harrell’s c-index), which
provides an estimate of the probability that the model will
correctly identify patients who had ≥pT3a.
Statistical analysis was performed using the SAS software
(SAS version 9.2) and R (R version 3.2.3) and its Hmisc and
rms libraries (http://cran.r-project.org/).
Results
The demographic and clinical characteristics of the 301 pa-
tients in our cohort are described in Table 1. Based on pre-
imaging clinical characteristics, there were 137 (45.5%) pa-
tients in the low-risk group (Fig. 1) and 164 (54.5%) in the
intermediate/high-risk group (Fig. 2).
Pathology findings
At final histology, pathology stage pT2c was the most fre-
quent (154 patients; 51.2%), followed by pathology stages
≥pT3a, pT2a, and pT2b (Table 1).
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mp-MRI findings
The majority of the patients were in PI-RADS v2 assessment
category 5 (62.5%), followed by categories 4 and 3; less than
2% of the patients were in category 2, and none in category 1
(Table 1). The distribution of PI-RADS assessment categories
was truncated below (no PI-RADS v2 assessment category 1
findings) in both groups and relatively flat for the low-risk
group. In contrast, it was skewed towards higher values in
the intermediate/high-risk group (Table 1).
The distribution of ESUR EPE scores was shifted towards
lower values in the low-risk group and towards higher values
in the intermediate/high-risk group (Table 1).
Univariate and multivariate associations
All evaluated clinical and tumor characteristics, except age,
were significantly associated with pathological stage ≥pT3a at
univariate analysis (Table 2). The same results were obtained
on stratifying by clinical risk groups (Supplementary Table 2).
Encompassing all risk groups, the performance of PI-
RADS v2 assessment category for ruling out ≥pT3a PCa
was described by SE, NPV, and LR− of 99%, 98%, and
0.04, respectively, and for ruling in ≥pT3a PCa by SP, PPV,
and LR+ of 23%, 46%, and 1.28, respectively (Table 3).
Encompassing all risk groups, the ESUR EPE score per-
formance for ruling out ≥pT3a PCa was described by SE,
NPV, and LR− of 78%, 85%, and 0.26, respectively, and for
ruling in ≥pT3a PCa by SP, PPV, and LR+ of 83%, 75%, and
4.59, respectively (Table 3).
Looking at the results stratified by risk groups (Table 3), the
performance of PI-RADS v2 assessment category and the
performance of ESUR EPE score were quite similar to the
above mentioned, with small increase of SE and PPV for both
PI-RADS v2 assessment category and ESUR EPE score in the
intermediate/high-risk group than in the low-risk group. A
small decrease in SP, LR−, and LR+ was also observed for
both PI-RADS v2 assessment category and ESUR EPE score
in the intermediate/high-risk group in respect to the low-risk
group.
The low clinical risk group was associated with a signifi-
cantly lower probability of ≥pT3a PCa than the intermediate/
high-risk group in all multivariable models (Table 4). Adding
either the ESUR EPE score or the PI-RADS v2 assessment
category to the clinical riskmodel (yieldingmodel 2 andmodel
3, respectively) significantly improved the prediction of ≥pT3a
PCa (model 2 AUC = 0.73, model 3 AUC= 0.86 relative to
clinical risk model AUC = 0.68, both p < 0.0001). The full
model (model 4, including PI-RADS v2 assessment category
and ESUR EPE scores as well as clinical risk group) produced
an AUC significantly higher than all the other models
(Supplementary Table 4), but the OR relative to model 3 (PI-
RADS v2 assessment category and clinical risk group) was not
significant. Similar results were obtained in analyses stratified
by clinical risk groups as presented in Supplementary Table 3.
ESUR EPE score and PI-RADS v2 assessment category
were seen to be significantly correlated (Spearman’s correla-
tion coefficient r = 0.55; p value < 0.0001).
Nomogram
The nomogram developed based on our cohort (Fig. 3) graph-
ically displays the predicted risk of ≥pT3a PCa in relation to
the combination of variables from the full model (model 4)
examined in the multivariate analysis: clinical risk group,
ESUR EPE score, and PI-RADS v2 assessment category.
The C-index for our nomogram was 0.8538.
Discussion
In our cohort of 301 operated prostate cancer patients, with a
prevalence of 39.5% ≥pT3a PCa, we observed an overall very
good performance of preoperative mp-MRI in ruling out
≥pT3a PCa using either PI-RADS v2 assessment category or
ESUR EPE score (PI-RADS v2 SE 99%, NPV 98%, LR−
0.04; ESUR EPE score SE 78%, NPV 85%, LR− 0.26). Our
results are comparable with those of Matsuoka et al [17] who
recently evaluated PI-RADS v2 in assessing extracapsular ex-
tension and demonstrated a SE of 92.9% and a high NPV
(96%), regardless of the risk group, in a cohort having a lower
prevalence of ≥pT3a PCa (26.7%), but are in contrast with
those of Gaunay et al [18] who saw comparatively low SE
(8.3%) and NPV (81.5%), but high SP (97.8%) and PPV
(93.3%) for the prediction of ≥pT3a PCa in a group of 74
operated prostate cancer patients where prevalence of ≥pT3a
PCa was 32.4%.
As regards ESUR EPE evaluation, our results are compa-
rable with those of Boesen et al [2], whose SE was 74% and
LR− was 0.295 in a population of 87 operated prostate cancer
patients with a ≥pT3a PCa prevalence of 37%. They are also
similar with those of Somford et al [19], who had a SE of
58.2% and LR− of 0.47 in a cohort of 183 prostate cancer
patients with a ≥pT3a PCa prevalence of 49.7%. Overall,
our results indicate somewhat higher sensitivity and lower
LR− than a recent meta-analysis of the mp-MRI in predicting
≥pT3a PCa that included 75 studies and 9796 patients, where
the overall SE was 57%, SP 91%, and LR− 0.47 for detection
of ≥pT3a PCa [5].
Both ESUR EPE score ≤ 2 and PI-RADS v2 assess-
ment category ≤ 3 were associated with a 96% lower risk
of ≥pT3a PCa than in patients with ESUR EPE score of
≥ 4 or PI-RADS v2 assessment category ≥ 4. The inclu-
sion of ESUR EPE score to the clinical risk alone (model
2) or PI-RADS v2 assessment category to the clinical
risk alone (model 3) significantly increased the AUC
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(from 0.68 to 0.86 (p < 0.0001) and to 0.73 (p < 0.0001),
respectively). Similar results were also obtained in both
the multivariate analyses stratified by clinical risk groups
(see Supplementary Material). The combined addition of
both ESUR EPE score and PI-RADS v2 assessment cat-
egory to clinical risk (model 4) yielded a slight but sta-
tistically significant further increase in AUC if compared
with model 2 (from 0.856 to 0.862 (p = 0.04)).
The similarity of performance in excluding ≥pT3a PCa
when adding either or both ESUR EPE score and PI-RADS
v2 assessment category to the clinical risk suggests a close
relationship between these two forms of assessment.
We found a correlation (r = 0.55) between PI-RADS v2
assessment categories and ESUR EPE score as indicators of
the presence of ≥pT3a PCa. It could be expected due to the
criteria that define the categories in the respective scales.
Table 1 Patient and tumor
characteristics of the study
population
Low-risk group
(N = 137)
Intermediate/high-risk group
(N = 164)
Total
(N = 301)
Age (years) 62.98 (± 6.98) 63.29 (± 6.96) 63.15 (± 6.96)
PSA (ng/ml) 5.98 (± 1.83) 10.89 (± 10.10) 8.66 (± 7.94)
Clinical stage
cT1b 0 (0.00%) 2 (1.22%) 2 (0.66%)
cT1c 109 (79.56%) 82 (50.00%) 191 (63.46%)
cT2a 28 (20.44%) 59 (35.98%) 87 (28.90%)
cT2b 0 (0.00%) 1 (0.61%) 1 (0.33%)
cT2c 0 (0.00%) 9 (5.49%) 9 (2.99%)
cT3a 0 (0.00%) 11 (6.71%) 11 (3.65%)
Biopsy Gleason score
3 + 3 137 (100.00%) 31 (18.90%) 168 (55.81%)
3 + 4 0 (0.00%) 70 (42.68%) 70 (23.26%)
4 + 3 0 (0.00%) 32 (19.51%) 32 (10.63%)
3 + 5 0 (0.00%) 3 (1.83%) 3 (1.00%)
4 + 4 0 (0.00%) 19 (11.59%) 19 (6.31%)
5 + 3 0 (0.00%) 2 (1.22%) 2 (0.66%)
4 + 5 0 (0.00%) 5 (3.05%) 5 (1.66%)
5 + 4 0 (0.00%) 2 (1.22%) 2 (0.66%)
ESUR EPE score
1 27 (19.71%) 9 (5.49%) 36 (11.96%)
2 50 (36.50%) 27 (16.46%) 77 (25.58%)
3 30 (21.90%) 34 (20.73%) 64 (21.26%)
4 22 (16.06%) 48 (29.27%) 70 (23.26%)
5 8 (5.84%) 46 (28.05%) 54 (17.94%)
PI-RADS v2 score
1 0 (0.00%) 0 (0.00%) 0 (0.00%)
2 2 (1.46%) 3 (1.83%) 5 (1.66%)
3 31 (22.63%) 6 (3.66%) 37 (12.29%)
4 39 (28.47%) 32 (19.51%) 71 (23.59%)
5 65 (47.45%) 123 (75.00%) 188 (62.46%)
Pathological stage
pT2a 13 (9.49%) 5 (3.05%) 18 (5.98%)
pT2b 3 (2.19%) 7 (4.27%) 10 (3.32%)
pT2c 93 (67.88%) 61 (37.20%) 154 (51.16%)
pT3a 25 (18.25%) 68 (41.46%) 93 (30.90%)
pT3b 3 (2.19%) 23 (14.02%) 26 (8.63%)
Expressed as N (%) or mean (± standard deviation)
Low-risk group: PSA < 10 and Gleason score ≤ 3 + 3 and clinical stage ≤ 2a according to [3]; intermediate/high-
risk group: the remaining patients
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Fig. 2 A right-sided,
posterolateral lesion in a 65-year-
old patient with a PI-RADS v2
score of 4 and EPE score of 2 at
mp-MRI examination seen in ax-
ial (a) T2-weighted image, (b)
subtracted DCE image, and (c)
ADC map. At histology, the axial
whole section of the apical por-
tion of the prostate (d—upper
right) without the posterolateral
surgical margins sampled for in-
traoperative examination revealed
a Gleason score 3 + 4 PCa. (d—
lower left). In the intraoperative
frozen section however, the PCa
(hashed zone) was found to be
pT3a, extending focally to the
surgical margin (unhashed zone),
including an extraprostatic site (*)
Fig. 1 mp-MRI examination
revealed an anterior, right lesion
having a PI-RADS v2 score of 5
in a 66-year-old, clinically low-
risk patient (cT1c, PSA 6.3, bi-
opsy Gleason score 3 + 3) seen in
(a) axial T2-weighted, (b) b1000
DWI, and (c) ADC map, where a
pT3a, pathologic Gleason score
3 + 4 cancer was identified in (d)
the histopathology specimen
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Explicit visualization of extraprostatic extent onmp-MRI is
a criterion for assigning a value of 5 under both PI-RADs v2
assessment category and ESUR EPE score criteria, resulting
in a concentration of ≥pT3a lesions in these categories by
construction. Even in the absence of visible extraprostatic ex-
tent, it has been demonstrated that the risk of ≥pT3a PCa is
associated with tumor contact length, with a risk rising from
below 10% when contact is < 10 mm, to about 40% when
contact is 15 mm, and over 60% when contact is > 20 mm
[20]. Moreover, it is recognized that low ADC values in index
lesions, a second condition leading to increased PI-RADS v2
assessment category values, are correlated with a higher
Gleason score that is in turn directly correlated with tumor
aggressiveness and consequently with risk of ≥pT3a PCa [21].
We note that our multivariate analyses suggest that the
ESUR EPE score is a slightly stronger factor in predicting
≥pT3a PCa than PI-RADS v2 assessment category.
Unfortunately, the evaluation of ESUR EPE score is not as
well standardized as PI-RADS v2 scoring system and remains
subjective, with low inter-observer agreement for the assess-
ment of pT3a having been reported by some authors [22, 23].
Thus, some effort towards standardization of ESUR EPE
score evaluation would appear to be a valuable contribution
to clinical practice. Until ESUR EPE score evaluation can be
reproducibly performed, the use of PI-RADS v2 assessment
categories provides a smaller, but significant, improvement in
the exclusion of ≥pT3a PCa that can be widely adopted.
The association between PI-RADS v2 and ≥pT3a PCa has
immediate clinical implications for patient care and manage-
ment of patients. As regards patient counseling, in particular
for functional preservation treatments, PI-RADS v2 assess-
ment categories 1, 2, and 3 effectively exclude ≥pT3a PCa
(risk notably less than 10%) and could promote suitability in
program of active surveillance. Conversely, the presence of
PI-RADS v2 assessment categories > 3 can inform the deci-
sion to avoid a nerve-sparing approach in the site of tumor
contact with capsule during radical prostatectomy, or to per-
form in that site intraoperative frozen sections [11].
Numerous nomograms have been developed for the pre-
diction of ≥pT3a, including the Partin tables and Memorial
Sloan Kettering Cancer Center (MSKCC) nomograms [24,
25], but these nomograms do not include the diagnostic con-
tribution of mp-MRI. Feng et al [26] compared the predictive
accuracy of MRI and clinical models (Partin tables and
MSKCC nomogram) for pT3a finding a small improvement
Table 2 Association of patient and tumor characteristics with ≥pT3a
PCa: univariate analysis
<pT3a ≥pT3a p value*
Overall cohort (N = 301, prevalence of ≥pT3a 39.5%)
Age (years) 62.64 (± 6.92) 63.93 (± 6.97) 0.11
Risk group < 0.0001
Low 109 (79.56%) 28 (20.44%)
Intermediate/high 73 (44.51%) 91 (55.49%)
ESUR EPE score
1–2 104 (92.04%) 9 (7.96%) < 0.0001
3 47 (73.44%) 17 (26.56%)
4–5 31 (25%) 93 (75%)
PI-RADS v2 score < 0.0001
1–2 5 (100.00%) 0 (0.00%)
3 36 (97.30%) 1 (2.70%)
4–5 141 (54.44%) 118 (45.56%)
Expressed as N (%) or mean (± std dev)
*Nonparametric two-sample Wilcoxon test for age and chi-square test for
categorical variables
Significant p values are in italics. Low-risk group: PSA < 10 and Gleason
score ≤ 6 and clinical stage ≤ 2a according to [3]; intermediate/high-risk
group: the remaining patients
Table 3 Sensitivity (SE), specificity (SP), positive and negative predictive values (PPVandNPV), and positive and negative likelihood ratios (LR+ and
LR−) for predicting ≥pT3a, according to risk group, PI-RADS v2, and EPE score
Variables N Prevalence
of ≥pT3a (%)
Ruling out performance Ruling in performance
SE* NPV* LR− SP* PPV* LR+
Risk group 76 (68–84) 80 (72–86) 0.39 60 (52–67) 55 (48–63) 1.91
ESUR EPE score 78 (70–85) 85 (79–90) 0.26 83 (77–88) 75 (66–82) 4.59
Low-risk group 137 20.4 64 (44–81) 91 (83–95) 0.40 89 (82–94) 60 (41–77) 5.84
Intermediate/high-risk group 164 55.5 82 (73–90) 77 (66–86) 0.24 74 (62–84) 80 (70–87) 3.17
PI-RADS v2 99 (95–100) 98 (87–100) 0.04 23 (17–29) 46 (39–52) 1.28
Low-risk group 137 20.4 96 (82–100) 97 (84–100) 0.12 29 (21–39) 26 (18–35) 1.37
Intermediate/high-risk group 164 55.5 100 (96–100) 100 (66–100) 0.00 12 (6–22) 59 (50–67) 1.14
*Expressed as % (95% CI)
CI, confidence interval. Low-risk group: PSA < 10 and Gleason score ≤ 3 + 3 and clinical stage ≤ 2a according to [3]; intermediate/high-risk group: the
remaining patients
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in diagnostic accuracy after addition of MRI to the models
(AUC for Partin tables and MSKCC of 0.85 and 0.86, respec-
tively, increased to 0.93 and 0.94 after addition of MRI).
Recently, Weaver et al [27] examined the incremental value
of prostate MRI when used in combination with the currently
available preoperative risk stratification tool, the MSKCC no-
mogram. They suggest that the use of prostate MRI as a pre-
dictive tool should be performed in combination with the clin-
ical risk stratification models.
The nomogram created from our cohort (Fig. 3) had a good
calibration index (0.8538), but it needs clinical validation and
development in other larger cohorts. Notably, while PI-RADS
v2 assessment category resulted in a not significant OR in the
full multivariate model, it has a strong influence on the scores
that are obtained using the nomogram. In particular, whereas
the ESUR EPE score can contribute a maximum of 45 points,
the PI-RADS v2 assessment category can contribute up to 100
points. The maximum value obtained from ESUR EPE score
Table 4 Modeling of patient and
tumor characteristics for
association with ≥pT3a PCa:
multivariate analysis
Model 1*
OR (95% CI)
Model 2*
OR (95% CI)
Model 3*
OR (95% CI)
Model 4*
OR (95% CI)
Overall cohort (N = 301, prevalence of ≥pT3a 20.4%)
Risk group
Intermediate/high Reference Reference Reference Reference
Low 0.21 (0.12–0.35) 0.41 (0.22–0.77) 0.26 (0.15–0.44) 0.43 (0.23–0.81)
ESUR EPE score
4–5 – Reference – Reference
3 – 0.14 (0.07–0.27) – 0.14 (0.07–0.28)
1–2 – 0.04 (0.02–0.09) – 0.05 (0.02–0.12)
PI-RADS v2 score
4–5 – – Reference Reference
1–2–3 – – 0.04 (0.01–0.32) 0.21 (0.03–1.67)
AUC 0.682 0.856 0.730 0.862
*Model 1 is based on risk group; model 2 is model 1 adding 3 classes ESUR EPE score; model 3 is model 1
adding 2 classes PI-RADS v2 score; model 4 is model 2 adding PI-RADS v2 score.OR, odds ratio;CI, confidence
interval; AUC, area under the curve. Significant ORs and 95% CI are in italics. Low-risk group: PSA < 10 and
Gleason score ≤ 3 + 3 and clinical stage ≤ 2a according to [3]; intermediate/high-risk group: the remaining patients
Fig. 3 Nomogram for the prediction of the risk of ≥pT3a PCa based on
clinical risk group, ESUR EPE score, and PI-RADS v2 score. For each
patient variable (Risk Group, ESUR EPE score, and PI-RADS v2), a
vertical line is drawn from the value on the bar for that variable to the
upper scale of points (dotted red lines show that low-risk group corre-
sponds to 0 points in the upper bar, ESUR EPE score 4–5 corresponds to
about 45 points, and PI-RADS v2 = 3 corresponds to 75 points). The sum
of these three points is then located on the scale indicating the BTotal
Points^ (here: 0 + 45 + 75 = 120 total points), and a vertical line is drawn
downwards (green dotted line). Where this line intersects, the scale for
Risk of ≥pT3a (%) gives the percentage risk of ≥pT3a PCa. Values out-
side the indicated bar should be read as risk < 10% (for Total Points <
100) or risk > 80% (for Total Points > 160), respectively. In the example
above, a subject in the low-risk group, with a ESUREPE score of 4–5 and
PI-RADS v2 score of 3 has about 28% risk of ≥pT3a PCa
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and group of risk is about 55 points that means a risk of ≥pT3a
PCa lower than 10%, but PI-RADS v2 assessment category
plays a decisive role in increasing the estimated risk for higher
≥pT3a PCa, which can rise to over 80% depending on PI-
RADS v2 assessment category.
A key limitation of our study relates to the fact that all
patients had undergone prostatectomy, of whom 54% were
of intermediate/high risk with the overall prevalence of
≥pT3a PCa being 39.5%. In addition, treatment decisions
were influenced by the original reporting of the mp-MRI un-
der PI-RADS v1, and thus the cohort may be subject to pos-
sible over- or underdiagnosis associated with that reporting
system. Due to patient choice to undergo surgery after positive
biopsy, there is a relatively high representation of low-risk
patients in our cohort (46%), but the proportion of PI-RADS
v2 scores ≤ 3 patients is low (15%). Thus, our results are most
applicable to a population with known prostate cancer, partic-
ularly intermediate- to high-risk disease, and cannot necessar-
ily be extrapolated to screening in the general population,
where the expected prevalence of PCa ranges from 5% at
age < 30 years to 59% by age > 79 years [28].
As well, we used consensus reporting by two radiologists
to improve accuracy of PI-RADS v2 category determinations.
This may limit the applicability of our results for single
readers in clinical practice. Reports indicate that inter-reader
reproducibility of PI-RADS v2 tends to be moderate and ex-
perience dependent [29, 30]. We would therefore expect that
expert single readers would have similar performance to that
reported in the present study.
Another limitation is that in our investigation of the predic-
tion of ≥pT3a PCa on a per-patient basis, there was no direct
comparison between the regions suspected of cancer based on
mp-MRI and the tumor focus detected at whole-mount histo-
pathologic examination. The data available retrospectively did
not allow analysis at the lobe level to be performed in this
study; a future work evaluating PI-RADS category scores
and adjacent EPE at a per lesion level would provide further
insight into the local depiction of ≥pT3a PCa and should cor-
relate the location of the suspicious lesions to the pathologic
stage.
Lastly, the nomogram developed based on our cohort must
be validated and tested for predictive ability in a larger popu-
lation of patients, and in other clinical centers.
In conclusion, the addition of PI-RADS v2 assessment cat-
egory to clinical risk parameters improves the prediction of
≥pT3a PCa, and thus risk stratification. In particular, PI-
RADS v2 assessment categories of 1 to 3 are useful for ex-
cluding ≥pT3a PCa with a NPVof 98%. This is important for
clinical practice and for appropriate patient counseling; as
such patients can be considered as candidates for less invasive
approaches (active surveillance, nerve-sparing surgery, or
prostate-only radiotherapy). The ESUR EPE score should be
better standardized to make full use of the available
information in evaluating prostate disease. A nomogram that
combines clinical and mp-MRI parameters for prediction of
≥pT3a PCa has been developed based on our cohort and re-
quires validation in larger and different populations prior to
use in clinical practice.
Funding The authors state that this work has not received any funding.
Compliance with ethical standards
Guarantor The scientific guarantor of this publication is Dr. Giuseppe
Petralia.
Conflict of interest The authors of this manuscript declare no relation-
ships with any companies, whose products or services may be related to
the subject matter of the article.
Statistics and biometry One of the authors has significant statistical
expertise.
Informed consent Written informed consent was waived by the
Institutional Review Board.
Ethical approval Institutional Review Board approval was obtained.
Study subjects or cohorts overlap Some study subjects, those who had
undergone RARP with nerve-sparing intent, have been described in a pub-
lication regarding the combined impact of mp-MRI and frozen section anal-
ysis on surgical outcomes. This appears in the article: Bianchi R, Cozzi G,
Petralia G et al Multiparametric magnetic resonance imaging and frozen-
section analysis efficiently predict upgrading, upstaging and extraprostatic
extension in patients undergoing nerve-sparing robotic-assisted radical pros-
tatectomy. Medicine (Baltimore). 2016 Oct;95(40):e4519.
Methodology
• retrospective
• diagnostic or prognostic study
• performed at one institution
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. National Comprehensive Cancer Network (NCCN) (2012) NCCN
clinical practice guidelines in oncology: prostate cancer. https://
www.nccn.org/professionals/physician_gls/default.aspx#site.
Accessed 7 July 2018
2. Boesen L, Chabanova E, Løgager V, Balslev I, Mikines K,
Thomsen HS (2015) Prostate cancer staging with extracapsular
extension risk scoring using multiparametric MRI: a correlation
with histopathology. Eur Radiol 25(6):1776–1785
3. Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate
MR guidelines 2012. Eur Radiol 22(4):746–757
Eur Radiol
4. Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS
Prostate Imaging-Reporting and Data System: 2015, Version 2.
Eur Urol 69(1):16–40
5. de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM
(2014) Accuracy of multiparametric MRI for prostate cancer detec-
tion: a metaanalysis. AJR Am J Roentgenol 202:343–351
6. Park JJ, Park BK (2017) Role of PI-RADSv2 with multiparametric
MRI in determining who needs active surveillance or definitive
treatment according to PRIAS. J Magn Reson Imaging 45(6):
1753–1759
7. American College of Radiology. PI-RADS™ prostate imaging -
reporting and data system 2015 v2. http://www.acr.org/~/media/
ACR/Documents/PDF/QualitySafety/Resources/PIRADS/
PIRADS-V2.pdf. Accessed 7 July 2018
8. Park SY, Jung DC, Oh YT et al (2016) PI-RADS version 2 helps
preoperatively predict clinically significant cancers. Radiology
280(1):108–116
9. Park SY, Oh YT, Dae CJ et al (2016) Prediction of biochemical
recurrence after radical prostatectomy with PI-RADS version 2 in
prostate cancers: initial results. Eur Radiol 26:2502–2509
10. Patel VR, Shah KK, Thaly RK, Lavery H (2007) Robotic-assisted
laparoscopic radical prostatectomy: the Ohio State University tech-
nique. J Robot Surg 1(1):15–59
11. Petralia G, Musi G, Padhani AR et al (2015) Robot-assisted radical
prostatectomy: multiparametric MR imaging-directed intraopera-
tive frozen-section analysis to reduce the rate of positive surgical
margins. Radiology 274(2):434–444
12. Epstein JI, AllsbrookWC Jr, AminMB, Egevad LL, ISUP Grading
Committee (2005) The 2005 International Society of Urological
Pathology (ISUP) consensus conference on Gleason grading of
prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242
13. Sobin LH, Gospodarowicz MK, Wittekind C (2011) TNM classi-
fication of malignant tumors, 7th edn.Wiley-Blackwell, Chichester,
pp 243–248
14. Tan PH, Cheng L, Srigley JR et al (2011) International Society of
Urological Pathology (ISUP) consensus conference on handling
and staging of radical prostatectomy specimens. Working group 5:
surgical margins. Mod Pathol 24(1):48–57
15. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines
on prostate cancer: part 1: screening, diagnosis, and local treatment
with curative intent - update 2013. Eur Urol 65:124–137
16. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing
the areas under two or more correlated receiver operating charac-
teristic curves: a nonparametric approach. Biometrics 44:837–845
17. Matsuoka Y, Ishioka J, Tanaka H et al (2017) Impact of the Prostate
Imaging Reporting and Data System, version 2, on MRI diagnosis
for extracapsular extension of prostate cancer. AJR Am J
Roentgenol 209(2):W76–W84
18. GaunayG, Patel V, Shah P et al (2017)Multi-parametricMRI of the
prostate: factors predicting extracapsular extension at the time of
radical prostatectomy. Asian J Urol 4:31–36
19. Somford DM, Hamoen EH, Fütterer JJ et al (2013) The predictive
value of endorectal 3 Tesla multiparametric magnetic resonance
imaging for extraprostatic extension in patients with low, interme-
diate and high-risk prostate cancer. J Urol 190:1728–1734
20. Baco E, Rud E, Vlatkovic L et al (2015) Predictive value of mag-
netic resonance imaging determined tumor contact length for
extracapsular extension of prostate cancer. J Urol 193(2):466–472
21. Giganti F, Coppola A, Ambrosi A et al (2016) Apparent diffusion
coefficient in the evaluation of side-specific extracapsular extension
in prostate cancer: development and external validation of a nomo-
gram in clinical use. Urol Oncol 34(7):291.e17
22. Soylu FN, Eggener S, Oto A (2012) Local staging of prostate can-
cer with MRI. Diagn Interv Radiol 18:365–373
23. Hole KH, Axcrona K, Lie AK et al (2013) Routine pelvic MRI
using phased-array coil for detection of extraprostatic tumour ex-
tension: accuracy and clinical significance. Eur Radiol 23(4):1158–
1166
24. Eifler JB, Feng Z, Lin BM et al (2013) An updated prostate cancer
staging nomogram based on cases from 2006 to 2011. BJU Int
111(1):22–29
25. Ohori M, Kattan MW, Koh H et al (2004) Predicting the presence
and side of extraprostatic extension: a nomogram for staging pros-
tate cancer. J Urol 171(5):1844–1849
26. Feng TS, Sharif-Afshar AR,Wu J et al (2015)MultiparametricMRI
improves accuracy of clinical nomograms for predicting
extracapsular extension of prostate cancer. Urology 86(2):332–337
27. Weaver JK, Kim EH, Vetter JM et al (2018) Prostate magnetic
resonance imaging provides limited incremental value over the
Memorial Sloan Kettering Cancer Center preradical prostatectomy
nomogram. Urology 113:119–128
28. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P (2015)
Prevalence of incidental prostate cancer: a systematic review of
autopsy studies. Int J Cancer 137(7):1749–1757
29. Smith CP, Hamon SA, Barrett T et al (2018) Intra- and interreader
reproducibility of PI-RADS v2: a multireader study. J Magn Reson
Imaging. https://doi.org/10.1002/jmri.26555
30. Ke Z, Wang L, Min XD et al (2018) Diagnostic performance and
interobserver consistency of the Prostate Imaging Reporting and
Data System Version 2: a study on six prostate radiologists with
different experiences from half a year to 17 years. Chin Med J
(Engl) 131(14):1666–1673
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Eur Radiol
